| Project/Area Number |
17591008
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
NIITSU Nozomi Saitama Medical University, Faculty of Medicine, Professor (20256697)
|
|---|
| Project Period (FY) |
2005 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥270,000)
Fiscal Year 2007: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2006: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2005: ¥1,600,000 (Direct Cost: ¥1,600,000)
|
|---|
| Keywords | Non-Hodgkin lymphoma / nm23-H1 / Rituximab / ELISA / RT-PCR |
|---|
| Research Abstract |
We previously detected nm23-H1 protein in the serum of patients with lymphoma, and developed a method of measuring the serum nm23-H1 level by ELISA. In patients with non-Hodgkin's lymphomas, we reported that a high serum nm23-H1 level was a poor prognostic factor. Since there are still many unanswered questions about the role of serum nm23-Hl protein in lymphomas, we studied nm23-H1 protein expression in lymphomas and its localization in cells by immunohistochemistry and performed functional analysis of nm23-H1 in lymphomas. (1) As one of the functional analyses of nm23-H1, we examined nm23 mRNA expression in lymphoma cells. We extracted RNA from lymph nodes and from lymphoid tissues of lymphomas and examined nm23 expression quantitatively by RT-PCR. We found that the level of mRNA expression of nm23-H1 was associated with the" or "was correlated with the serum nm23-H1 level and found that it was a prognostic factor of lymphoma similar to serum nm23-H1 (2) High serum nm23-H1 was a poor
… More
prognostic factor for not only untreated non-Hodgkin lymphoma cases but also relapsed cases, and a prognostic factor in patients with lymphoma that was refractory to chemotherapy. In addition, we reported that high serum nm23-H1 was associated with early relapse. (3) In patients with Hodgkin's lymphoma, we examined serum and intracytoplasmic nm23, and intracytoplasmic nm23 was found in a large percentage of Hodgkin's cells. In addition, the levels of serum and intracytoplasmic nm23-H1 were independent prognostic factors in patients with Hodgkin's lymphoma similar to patients with non-Hodgkin's lymphomas. (4) We examined whether high serum nm23-H1 was a prognostic factor for diffuse large B-cell lymphoma. In diffuse large B-cell lymphoma that was treated with rituximab combination chemotherapy, we found that nm23-H1 became an independent prognostic factor. (5) In primary thyroid lymphomas and primary breast lymphomas, we found that nm23-H1 overexpression was a significant poor prognostic factor. Less
|
